InspireMD Reports Q3 2025 Earnings with Revenue Growth and Net Loss
InspireMD (NSPR) reported Q3 2025 earnings with total revenue of $2.5 million, showing strong year-over-year and sequential growth. However, the company posted a net loss of $12.7 million, driven by increased operating expenses. The results were influenced by the launch of CGuard Prime in the U.S. and international expansion.
Tickers: $NSPR
Topics: FDA Approval Financial Performance Revenue Growth U.S. Market Expansion